Featured
-
-
Article |
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
A novel neutralizing antibody from a healthy HIV-1-infected donor that is specific for the membrane proximal region of gp41 is reported; the antibody has high potency and breadth, is not autoreactive and does not bind phospholipids.
- Jinghe Huang
- , Gilad Ofek
- & Mark Connors
-
Comment |
Towards a cure for HIV
Steven G. Deeks and Françoise Barré-Sinoussi present an international research agenda to seek out a cure for AIDS.
- Steven G. Deeks
- & Françoise Barré-Sinoussi
-
Comment |
Bring safe sex to China
China's discomfort over discussing sex, and especially homosexuality, is a major problem when it comes to HIV, says a consortium of researchers in China.
- Hong Shang
- , Junjie Xu
- & Linqi Zhang
-
-
News |
Monkey vaccine hints at how to stop HIV
Study could help researchers developing a human vaccine.
- Ewen Callaway
-
Letter |
Broad neutralization coverage of HIV by multiple highly potent antibodies
- Laura M. Walker
- , Michael Huber
- & Pascal Poignard
-
Research Highlights |
Long-term fix for SCID kids
-
News |
Gene-therapy successes spur hope for embattled field
Technique now being tested in a range of conditions.
- Erika Check Hayden
-
Letter |
Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy
- Alex Sigal
- , Jocelyn T. Kim
- & David Baltimore
-
Research Highlights |
Antibody search hits gold
-
News & Views |
Going for the watchman
A protein called SAMHD1 seems to hinder the infection of key cells of the immune system by HIV-1. Cousins of this virus, however, produce a factor that overcomes the protective effects of SAMHD1. See Letters p.654 & p.658
- Efrem S. Lim
- & Michael Emerman
-
News Q&A |
Treatment is prevention
Drug treatment for HIV infection is effective in preventing its spread, but implementing this fully will require more resources, says leading NIH scientist.
- Erika Check Hayden
-
News |
Cash cure for the AIDS epidemic?
South African researchers are testing whether financial incentives can stop HIV infection in teenagers.
- Priya Shetty
-
Editorial |
A big disease with a little name
Three decades on from the first published cases of what would later be recognized as AIDS, the social and cultural challenges of the disease remain.
-
Comment |
Children of the AIDS pandemic
Practical support and psychosocial interventions are desperately needed to help those dealing with the fallout of AIDS, says Lucie Cluver.
- Lucie Cluver
-
Comment |
Stigma impedes AIDS prevention
Medical advances cannot help those who deny they are at risk of HIV and avoid HIV tests. Salim S. Abdool Karim describes how such attitudes may be overcome.
- Salim S. Abdool Karim
-
News & Views |
Persistence pays off
Developing AIDS vaccines has been a frustrating business. A vaccine that triggers immune responses that effectively control early infection by the simian counterpart of HIV in macaques seems promising. See Letter p.523
- R. Paul Johnson
-
-
Perspective |
A 2020 vision for vaccines against HIV, tuberculosis and malaria
- Rino Rappuoli
- & Alan Aderem
-
News |
AIDS mortality drops in China
Antiretroviral programme marks dramatic success, but report shows what still needs to be done.
- David Cyranoski
-
Letter |
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine
- Scott G. Hansen
- , Julia C. Ford
- & Louis J. Picker
-
News |
Targeted gene editing enters clinic
Patients with HIV first to receive experimental gene therapy.
- Heidi Ledford
-
News & Views |
Drugs that prevent HIV infection
Two human trials investigate the efficacy of a type of antiretroviral drug — usually used to treat HIV-infected individuals — in preventing HIV infection. The results are heartening.
- Mark A. Wainberg
-
News |
Drugs to treat HIV found to prevent infection
Antiretroviral drugs shown to cut HIV transmission to men at high risk.
- Alla Katsnelson
-
News |
HIV immunity is all in the amino acids
Worldwide study implicates structural changes in a protein binding site
- Joseph Milton
-
Letter |
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation
During immune responses, antibodies are selected for their ability to bind to foreign antigens with high affinity, in part by their ability to undergo homotypic bivalent binding. However, this type of binding is not always possible. Here, the monoclonal antibodies produced in two infected subjects in response to human immunodeficiency virus (HIV) glycoprotein have been analysed. The results provide evidence for polyreactivity, which may be required when the density of glycoprotein spikes is so low that bivalent binding is unlikely.
- Hugo Mouquet
- , Johannes F. Scheid
- & Michel C. Nussenzweig
-
News |
Therapeutic HIV vaccines show promise
Clinical trials hint that treatment strategy is not a dead end.
- Alison Abbott
-
-
News |
Souped-up antibody fends off HIV
Targeted search yields proteins that neutralize nearly all HIV strains.
- Heidi Ledford
-
News |
Well-trained immune cells keep HIV in check
Differences in T-cell development may explain why some infected people do not develop AIDS.
- Alla Katsnelson
-
Letter |
Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection
'Elite controllers' are rare people who are infected with HIV but maintain low levels of HIV RNA without being treated, making it unlikely that they will develop AIDS. Certain HLA class I alleles, notably HLA-B57, are enriched in elite controllers. Here a model is proposed to explain how such elite controllers generate an effective immune response against HIV. In this model, HLA-B57 binds to fewer self-peptides, resulting in a T-cell repertoire with enhanced cross-reactivity and leading to a more effective T-cell response to the virus.
- Andrej Košmrlj
- , Elizabeth L. Read
- & Arup K. Chakraborty
-
Research Highlights |
Immunology: Misplaced target
-
-
-
Opinion |
Accelerating HIV vaccine development
Translational-research programmes supported by flexible, long-term, large-scale grants are needed to turn advances in basic science into successful vaccines to halt the AIDS epidemic, says Wayne C. Koff.
- Wayne C. Koff
-
News |
Hiding place for HIV revealed
The AIDS virus escapes treatment inside progenitor blood cells.
- Janet Fang
-
News |
'Seek, test and treat' slows HIV
Studies in several nations show that treating people before they fall ill can curb the spread of disease.
- Erika Check Hayden
-
Opinion |
AIDS research must link to local policy
HIV research in South Africa is world class. To halt the country's epidemic, scientists need to shift focus from global problems to priorities at home, say Salim Abdool Karim and Quarraisha Abdool Karim.
- Salim S. Abdool Karim
- & Quarraisha Abdool Karim
-
News |
Untangling HIV transmission in men
Study could put scientists on the right path to blocking the spread of new infections.
- Erika Check Hayden
-
Column |
Better all the time
Innovation policies are more likely to be successful if they leverage existing capabilities, argues Daniel Sarewitz.
- Daniel Sarewitz
Breast-milk molecule raises risk of HIV transmission
Algeria to tackle HIV/AIDS
Vaccines: His best shot
Immunology and the elusive AIDS vaccine
Targeting early infection to prevent HIV-1 mucosal transmission